Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2-breast cancer

被引：0
|
作者：
Bilani, Nadeem
Yaghi, Marita
Saravia, Diana
Jabbal, Iktej
Zerdan, Maroun Bou
Elson, Leah
Hong, Liang
Nahleh, Zeina
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-08-33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-08-33
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [12] A multinational study of real-world treatment patterns among patients with early stage HR+/HER2-breast cancer (BC)
    Criscitiello, C.
    Spurden, D.
    Rider, A.
    Williams, R.
    Corsaro, M.
    Pike, J.
    Law, E. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S42 - S43
  • [13] Comprehensive genomic profiling of advanced HR+/HER2-breast cancer patients using liquid biopsy
    Shao, B.
    Tang, H.
    Liu, X-R.
    Song, G.
    Di, L.
    Xie, F.
    Jia, C.
    Zhang, Y.
    Jia, S.
    Li, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389
  • [14] ADOPTION OF MULTI-GENE ASSAYS IN HR +, HER2-BREAST CANCER (BC) PATIENTS IN EUROPE: RESULTS OF THE MULTIDISCIPLINARY APPLICATION OF GENOMICS IN CLINICAL PRACTICE (MAGIC) SURVEY
    Aapro, M. S.
    De Laurentiis, M.
    Mamounas, E.
    Martin, M.
    Rea, D.
    Rouzier, R.
    Smit, V.
    Thomssen, C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [15] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
  • [16] Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2-breast cancer
    Corti, Chiara
    Chu, Xiangying
    Exman, Pedro
    Kline, Danielle
    Priedigkeit, Nolan
    Tayob, Nabihah
    Mayer, Erica
    Waks, Adrienne
    Hughes, Melissa
    Giordano, Antonio
    Curigliano, Giuseppe
    Lin, Nancy
    King, Tari
    Jeselsohn, Rinath
    Dillon, Deborah
    Mittendorf, Elizabeth
    Tolaney, Sara
    CANCER RESEARCH, 2024, 84 (09)
  • [17] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [18] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN HR+/HER2-EARLY STAGE BREAST CANCER
    Criscitiello, C.
    Wild, R.
    Rider, A.
    Williams, R.
    Mitra, D.
    Bambrick, C.
    Kurosky, S.
    VALUE IN HEALTH, 2020, 23 : S480 - S480
  • [19] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Vollbrecht, Claudia
    Hoffmann, Inga
    Lehmann, Annika
    Merkelbach-Bruse, Sabine
    Fassunke, Jana
    Wagener-Ryczek, Svenja
    Ball, Markus
    Dimitrova, Lora
    Hartmann, Arndt
    Stohr, Robert
    Erber, Ramona
    Weichert, Wilko
    Pfarr, Nicole
    Bohlmann, Lisa
    Jung, Andreas
    Dietmaier, Wolfgang
    Dietel, Manfred
    Horst, David
    Hummel, Michael
    VIRCHOWS ARCHIV, 2023, 482 (04) : 697 - 706
  • [20] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Claudia Vollbrecht
    Inga Hoffmann
    Annika Lehmann
    Sabine Merkelbach-Bruse
    Jana Fassunke
    Svenja Wagener-Ryczek
    Markus Ball
    Lora Dimitrova
    Arndt Hartmann
    Robert Stöhr
    Ramona Erber
    Wilko Weichert
    Nicole Pfarr
    Lisa Bohlmann
    Andreas Jung
    Wolfgang Dietmaier
    Manfred Dietel
    David Horst
    Michael Hummel
    Virchows Archiv, 2023, 482 : 697 - 706
12345